MedTrace Logo

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

NCT00484536 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2011-09-12

No results posted yet for this study

Summary

The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis

Conditions

Interventions

DRUG

CDP323

250 mg capsules, 500 mg bid (1000 mg/day)

DRUG

placebo

capsules, once daily

DRUG

CDP323

250 mg Capsules, 500 mg, once daily

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-11-30
Completion
2010-07-31

Countries

  • United States
  • Belgium
  • Canada
  • Finland
  • France
  • Germany
  • Hungary
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484536 on ClinicalTrials.gov